每年出版 4 期
ISSN 打印: 0893-9675
ISSN 在线: 2162-6448
Indexed in
Prostate Cancer Biomarkers: Current Status
摘要
Prostate cancer (PCa) is the second most frequently diagnosed cancer among men worldwide. Given the biological heterogeneity in localized PCa and its variable clinical course, a personalized approach to patient risk stratification and management is needed. A variety of high-throughput technologies, such as next-generation sequencing, transcriptomic, epigenetic, and metabolomic modalities have led to an improved understanding of the genomic basis of PCa and the identification of PCa biomarkers. Novel genomic approaches offer additional information to improve clinical decision making. The goal of this report is to review the use of currently available molecular biomarkers in the diagnosis and prognostication of PCa outcome.
-
Nevirovich E. S., Shestopalova O. Yu., Yakovenko A. A., Rumiantsev A. Sh., Matveeva Yu. V., Experience in the use of MRI-ultrasound fusion-targeted biopsy of the prostate for the diagnosis of prostate cancer, VESTNIK KHIRURGII IMENI I.I.GREKOVA, 177, 5, 2018. Crossref
-
McGrowder Donovan, Anderson-Jackson Lennox, Dilworth Lowell, Mohansingh Shada, Anderson Cross Melisa, Bryan Sophia, Miller Fabian, Wilson-Clarke Cameil, Nwokocha Chukwuemeka, Alexander-Lindo Ruby, McFarlane Shelly, The Clinical Usefulness of Prostate Cancer Biomarkers: Current and Future Directions, in Cancer Bioinformatics [Working Title], 2022. Crossref
-
Londoño Diana P, Arumaithurai Kogulavadanan, Constantopoulos Eleni, Basso Michael R, Reichard R Ross, Flanagan Eoin P, Keegan B Mark, Diagnosis of coexistent neurodegenerative dementias in multiple sclerosis, Brain Communications, 4, 4, 2022. Crossref